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Abstract Hematological parameters and the state of liver
cells of rats were examined in vivo after the animals
received aﬂatoxin B1 (AfB1) alone and together with
modiﬁed nanodiamonds (MND) synthesized by detonation.
The rats that had received the MND hydrosol had elevated
leukocyte levels, mainly due to higher granulocyte counts
and somewhat increased monocyte counts compared to
control rats. Hematological parameters of the rats that had
received AfB1 alone differed from those of the control rats
in another way: total white blood cell counts were signif-
icantly lower due to the decreased lymphocyte counts. In
rats that had consumed AfB1 with the MND hydrosol,
changes in hematological parameters were less pronounced
than in rats that had consumed either AfB1 or MND.
Electron microscopy showed that hepatocytes of the rats
that had received the MND hydrosol or AfB1 with the
MND hydrosol contained elevated levels of lipid inclusions
and lysosomes. Hyperplasia of the smooth endoplasmic
reticulum (EPR) was revealed in liver specimens of the rats
that had received AfB1. Results of the study suggest the
conclusion about mutual mitigation of the effects of
nanoparticles and the mycotoxin on rats blood and liver
cells after AfB1 has adsorbed on MND.
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Introduction
Aﬂatoxins are secondary metabolites produced by Asper-
gillus—a widely occurring genus of mold fungi. Food and
feed products infested by mold fungi can be contaminated
with aﬂatoxins. This is a serious hazard to animal and
human health, as aﬂatoxins are mutagenic and carcino-
genic. Aﬂatoxin B1 (AfB1) is the most hazardous myco-
toxin in this group, and there is no threshold concentration
for its toxic effect. The main target of AfB1 is liver and it
undergoes transformations in hepatocytes: biotransforma-
tion to active AfB1-8,9-epoxide, which gets bound with
DNA; irreversible hydroxylation, forming metabolites M1,
P1, and Q1; reversible hydroxylation, forming aﬂatoxicol
[1–5]. Aﬂatoxins that come into animal and human gas-
trointestinal systems with contaminated food can be miti-
gated by various enterosorbents [6–9].
Modiﬁed nanodiamonds (MND) synthesized by deto-
nation can be proposed as intestinal adsorbent of myco-
toxins. A highly developed MND surface, as well as the
presence of various chemically active functional groups,
hydrocarbon fragments, and metal microimpurities on the
surface of nanoparticles, determines their high afﬁnity for
sorption of biomolecules [10–12]. Some physicochemical
properties of the nanodiamond surface are presented in the
work of Gibson et al. [13]. MND have good colloidal
stability in dispersion media and are adapted for biological
and medical studies. Thus, MND hydrosols can be used for
all kinds of injections and oral administration of nanopar-
ticles to animals in long-duration experiments. We proved
in animal experiments that MND are highly biocompatible
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Schrand et al. [15].
In this study, we examined the effect of AfB1 on
hematological parameters and the state of liver cells of rats
that orally received AfB1 alone and together with MND.
Experimental Works
Rats
Experiments were conducted on adult Wistar rats, which
were kept in a vivarium, under similar conditions. The rats
were randomly divided into 4 groups (3 animals per group).
Every rat was kept in its own cage. Animals of the control
(Group 1) drank water. Animals of the treatment groups
drank an MND hydrosol containing 0.4 wt% nanoparticles
(Group 2), an aqueous solution of AfB1 (Group 3), an
MND hydrosol (0.4 wt%) containing AfB1 (Group 4).
Every rat of groups 3 and 4 received the amount of the
liquid proportional to its body mass. Thus, the total
amounts of AfB1 per 1 g weight orally received by the rats
were equal for all animals of these groups. After the rats
had consumed the AfB1-containing liquids for 10 days,
they received water (Group 3) or MND hydrosol (Group 4)
within approximately 25 days. This 25-day period was
used for a more complete manifestation of the cumulative
effect of the AfB1 in animals. The total duration of the
experiment was 35 days.
Aﬂatoxin B1
AfB1 used in this study was analytical grade and supplied
by «Ecolan» (Russia) as the standard for HPLC. One
ampoule contained 10 lg mycotoxin dissolved in 1 mL
acetonitrile. Aqueous AfB1 solution was prepared by
substituting distilled water for acetonitrile.
Preparation of MND and MND with AfB1
MND of 4- to 250-nm grade (Brand RUDDM 0–0.25)
produced by detonation in ‘‘Real-Dzerzhinsk’’ Ltd. (Rus-
sia) were used in the experiments. The MND hydrosol
(0.4 wt%) was prepared by adding distilled water to
nanoparticle powder. The AfB1-containing MND hydrosol
was prepared by adding a mycotoxin aqueous solution to
the nanoparticle hydrosol. The amounts of free AfB1 and
AfB1 bound with nanoparticles were determined by spec-
tral analysis. For this purpose, after adding AfB1 aqueous
solution to the MND hydrosol samples, they were stirred in
a Vortex-Genie 2 g-560E (Scientiﬁc Industries, Inc., USA)
for 10 s and incubated for 2 min at room temperature,
and the particles were then collected by centrifugation
(Centrifuge 5415R, Eppendorf, Germany) at 14,100g for
10 min. The ability of nanoparticles to coagulate was used
for their more complete removal. For this purpose, the
specimens were supplemented with NaCl at a concentra-
tion of 80–100 mM before centrifugation. The supernatants
obtained were assessed by spectral analysis in the range of
200–500 nm at an UVIKON-943 UV/VIS spectrophoto-
meter (Kontron Instruments, Italy).
Hematological and Electron Microscopic Analyses
After the end of the experiment, we took samples of blood
from the animals for hematological analysis. Hematologi-
cal parameters were evaluated using an ABX MICROS-60
hematology analyzer (France). Then the rats were killed, in
compliance with the euthanasia principles, and liver sam-
ples were taken for transmission electron microscopic
(TEM) examination. Liver tissue samples were ﬁxed in
2.5% glutaraldehyde in 0.1 M cacodylate buffer at pH 7.2;
then they were additionally ﬁxed in a 1% OsO4 solution in
the same buffer. The samples were dehydrated in graded
series of ethanol and in acetone; then they were embedded
in Epon 812-Araldite M epoxy resin mixture (‘‘Serva’’).
Ultrathin sections were cut using a Reichert Um-03 ultra-
microtome (Austria) and stained with a 3% of uranil ace-
tate in 30% ethanol solution and 0.2% aqueous solution of
lead citrate and examined in the JEM 1400 (JEOL, Japan).
The data were statistically processed by Microsoft Excel
2003 software. The conﬁdence level was a = 0.05.
Results and Discussion
Our earlier in vitro experiments have demonstrated that the
addition of MND leads to a rapid AfB1 adsorption by
nanoparticles, the incubation time does not exceed 2–3
min. An increase in the incubation time from several
minutes to several hours did not elevate the amount of
adsorbed mycotoxin [11]. It has been showed (Fig. 1) that
the AfB1 sorption capacity of MND depends on the ratio of
the mycotoxin to sorbent. For example, the data demon-
strate that the adsorption of small AfB1 amounts reaches
60% at 25 mg of MND in the sample (1 mL); however,
MND sorption capacity in this case is low. With an
increase in the amounts of the mycotoxin, the sorption
capacity of nanoparticles elevates by one order of magni-
tude. Analogously, an increase in the MND amount leads
to an increase in the amount of the bound mycotoxin;
however, the sorption capacity in this case decreases.
It is well known that animal species exhibit different
resistance to the toxic and carcinogenic effect of AfB1.
That was the reason why we performed experiments on
rats: they are more sensitive to AfB1 than, e.g., mice [16].
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123Each rat of Group 3 received 0.1 lg AfB1 per gram weight
throughout the experiment. The same amount of AfB1 was
administered orally with the MND hydrosol to each animal
of Group 4. Spectral analysis showed that 81% of the
mycotoxin contained in the MND hydrosol was adsorbed
on nanoparticles, and 19% was free (Fig. 2).
Analysis of blood samples taken from animals of dif-
ferent groups showed the following differences in hema-
tological parameters (Fig. 3). The blood of rats of Group 2
contained considerably higher leukocyte levels than the
blood of control animals (Group 1), probably due to a
considerable increase in granulocytes. Previously, we made
the assumption that the increase in the total level of white
blood cells in mice that orally received MND could be a
consequence of the interaction between nanoparticles and
gastrointestinal macrophages [17]. The Group 3 rats had
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Fig. 2 Spectral parameters of the aqueous solution of AfB1 and the
supernatant resulting from mixing of the AfB1 aqueous solution and
the MND hydrosol and subsequent centrifugation to remove nano-
particles with adsorbed mycotoxin
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Fig. 3 Leukocyte levels in the blood of rats that orally received water
(control), the MND hydrosol, the AfB1 aqueous solution, and AfB1
with the MND hydrosol. Note: WBC leukocytes, LYM lymphocytes,
MON monocytes, GRA granulocytes. Hematological parameters were
determined at the end of experiment
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Fig. 4 Red blood cells (a) and platelet counts (b) in the rats of the
treatment groups and the control animals. Hematological parameters
were determined at the end of experiment
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Fig. 1 MND sorption characteristics depending on the AfB1 content
in specimen at a constant amount of nanoparticles (a) and depending
on the content of nanoparticles in specimen at a constant amount of
AfB1 (volume 1 mL) (b)
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123lower leukocyte levels, evidently due to a considerable
(more than twofold) decrease in lymphocyte counts. This
may be indicative of the deterioration of immune status in
the rats of this group in response to the toxic effect of
AfB1. The literature data suggest that different doses of
AfB1 can either stimulate or suppress the immune system
of the organism [18–20]. Group 4 animals, which had
received AfB1 with the MND hydrosol, exhibited less
pronounced dissimilarities in the total leukocyte level,
including those in lymphocyte and granulocyte counts,
from the respective parameters of Group 1 rats.
No signiﬁcant differences were found between erythro-
cyte counts of any of the treatment rats and the control
group (Fig. 4a). Platelet counts were higher in the animals
of Group 2 and 3 (Fig. 4b). However, the platelet counts in
the blood of the Group 4 rats were similar to those of the
Group 1 animals. In our opinion, these results may suggest
mutual mitigation of the effects of MND and AfB1 (after
the mycotoxin has adsorbed on nanoparticles) on white
blood cells. The same explanation can be proposed for the
registered differences in platelet counts between the treat-
ment animals and the control group.
The mutagenic and carcinogenic effects of AfB1 are
related to the formation of its reactive exo-8,9-epoxide
metabolite, which gets ﬁrmly bound with DNA. Bioacti-
vation of AfB1 occurs in hepatocytes and are effected by
the system of cytochrome P450, localized on membranes of
the smooth EPR [1, 21, 22]. Analysis of ultrathin sections
showed differences in the structure of liver cells between
the rats of the treatment groups and the control animals
(Fig. 5). Hepatocytes of the rats of Group 2 (Fig. 5b) were
observed to contain elevated amounts of lysosomes and
aggregates of lipid inclusions of low electron density.
These changes in the hepatocyte ultrastructure could be a
result of the compensatory response of the organism to the
oral administration of MND. Electron microscopic analysis
of hepatocytes of the Group 3 rats that had consumed AfB1
alone showed hyperplasia of smooth EPR, which could be
indicative of its hyperfunction (Fig. 5c). Importantly, no
similar changes were observed in the hepatocyte ultra-
structure of the rats that had consumed AfB1 with the MND
hydrosol (Fig. 5d). The registered lysosome aggregates in
hepatocytes and the presence of electron-dense inclusions
in bile capillaries can be indicative of active degradation of
Fig. 5 Ultrastructure of hepatocytes of animals: a Group 1 rats that
orally received water, b Group 2 rats that orally received the MND
hydrosol, c Group 3 rats that orally received the AfB1 aqueous
solution, d Group 4 rats that orally received AfB1 with the MND
hydrosol. Bar—2 lm. Arrows show hyperplasia of smooth endoplas-
mic reticulum in hepatocyte image. Note: n nucleus, m mitochondria,
lip lipid inclusions, ly lysosomes
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123foreign compounds and their elimination from the cells.
Excess accumulation of lipid inclusions in hepatocytes was
also reported by author, who used intestinal adsorbents to
treat various intoxications [23].
Conclusion
Thus, results of the examination of hematological param-
eters of blood and the state of the rats liver cells can sug-
gest that oral administration of AfB1 together with the
MND hydrosol produces a less toxic effect on animals than
oral administration of AfB1 alone. After AfB1 has been
adsorbed on MND, the effects of the mycotoxin and
nanoparticles should be mutually mitigated. Our previous,
in vitro, experiments proved that MND can adsorb AfB1
from aqueous solutions with subacid, acid, and alkaline pH,
which are characteristic of different sections of the gas-
trointestinal system [11]. Another advantage of MND as
intestinal adsorbent is the high rate of AfB1 adsorption (the
process taking not more than 2–3 min) and very good
biocompatibility of nanoparticles, proven by in vivo
experiments with animals of various species [14]. Hence,
MND can be proposed as intestinal adsorbent to bind and
neutralize mycotoxins, AfB1 in particular.
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